<DOC>
	<DOCNO>NCT02864498</DOCNO>
	<brief_summary>The purpose study determine whether orally administer DS107 ( 1g 2g dos ) effective treatment moderate severe atopic dermatitis . Oral DS107 capsule administer 8 week compare placebo . The study enroll approximately 300 subject .</brief_summary>
	<brief_title>Efficacy Safety Study Orally Administered DS107 Moderate Severe Atopic Dermatitis Patients</brief_title>
	<detailed_description>The study consist 3 treatment arm , consist approximately 100 subject . Treatment Arm 1 receive 1g Oral DS107 daily . Treatment Arm 2 receive 2g Oral DS107 daily . Treatment Arm 3 receive placebo daily . The primary objective study assess efficacy safety daily 1g 2g dos Oral DS107 versus placebo . Subjects come clinic 7 occasion : Screening , Baseline , Week 2 , Week 4 , Week 6 , Week 8 ( end treatment/early termination ) Week 10 ( follow-up ) . The primary efficacy variable IGA ( Investigator 's Global Assessment ) . Secondary efficacy variable include IGA , EASI ( Eczema Area Severity Index ) , NRS ( Numeric Rating Scale ) ,</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Subjects clinically confirm diagnosis active Atopic Dermatitis accord Hanafin Rajka criterion Subjects moderate severe Atopic Dermatitis baseline define IGA minimum 3 baseline Subjects Atopic Dermatitis cover minimum 10 % body surface area baseline Male female subject age 18 year old day signing inform consent form ( ICF ) Subjects skin condition might interfere Atopic Dermatitis diagnosis and/or evaluation ( psoriasis current active viral , bacterial fungal skin infection ) assess Investigator Subjects use systemic treatment ( biologics ) could affect Atopic Dermatitis le 4 week prior baseline visit ( Day 0 ) , e.g . retinoids , methotrexate , cyclosporine , hydroxycarbamide ( hydroxyurea ) , azathioprine oral/injectable corticosteroid . Intranasal corticosteroid inhale corticosteroid stable medical condition allow Subjects use topical medicate treatment Atopic Dermatitis two week prior start treatment/Baseline ( Day 0 ) , include limited , topical corticosteroid , tar bleach Subjects use topical product contain urea , ceramides hyaluronic acid two week prior Baseline Subjects history hypersensitivity substance Oral DS107 placebo capsule Subjects clinically significant control uncontrolled medical condition laboratory abnormality would , opinion investigator , put subject undue risk interfere interpretation study result Subjects significant uncontrolled cardiovascular , neurologic , malignant , psychiatric , respiratory hypertensive disease , well diabetes arthritis illness , opinion investigator , likely interfere completion study Subjects medical history chronic infectious disease ( e.g . hepatitis B , hepatitis C infection human immunodeficiency virus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>